April 11, 2014

BioCorRx, Inc. CEO Kent Emry Featured on Bloomberg TV's Taking Stock with Pimm Fox

Los Angeles, April 11, 2014 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX), CEO Kent Emry was featured yesterday on Bloomberg Television's *Taking Stock with Pimm Fox* alongside Start Fresh Program alum Jeremy Miller.   BioCorRx, Inc. is a leader in addiction treatment and rehabilitation programs across the country. The company's Start Fresh Program treats addiction through the use of a proprietary implant containing the FDA-approved pharmaceutical, Naltrexone. Emry discussed that BioCorRx, Inc. is excited about entering into the opioid addiction treatment market, as Naltrexone is equally if not more effective in combating opioid addiction which includes heroin addiction. When asked how well the implant works Jeremy responded "It saved my life. It was like someone flicking off a light switch, that's how drastic the feeling was. I went from obsessing about my next drink all day long, every moment of the day, to couldn't have cared less whether I had a drink or not, inside of about three hours."

[The full segment on Bloomberg can be seen by clicking here](#)

BioCorRx plans to capture market share from this $23 Billion industry by offering a program that, unlike most of its competitors, can effectively reduce or virtually eliminate the physical cravings associated with addiction in most people. "Our country has traditionally focused on the psycho-social reasons why people drink. What's neat about this is it addresses that physical need. All of a sudden now we take care of those cravings, and can really dig into the psycho-social reasons". For addicts like Jeremy, the physical aspect of addiction was the most significant barrier on the path to recovery. "Not only has Jeremy beat his addiction, but as a well-known actor, he is using his voice to speak out and help others by spreading the word about this incredible program. We are very proud of him", said Emry.

Recent Media

[Fox Business with Dr. Manny Alvarez](#)

[The Doctors: Battling Alcohol Abuse](#)

[theStreet.com featuring COO Brady Granier on Opioid Addiction](#)

[Healthline News featuring Advisory Board Member George Fallieras M.D.](#)

[BioCorRx's Start Fresh Program Alum Jeremy Miller featured in InTouch Weekly](#)

[The Stock Radio featuring COO Brady Granier](#)

About BioCorRx, Inc.

BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of substance abuse addiction treatment. The company has developed a highly effective program called the Start Fresh Program^{TM} consisting of two components used by various addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. For more information on BICX, visit www.BioCorRx.com

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

```
CONTACT: Investor Relations

        SmallCapVoice.Com, Inc.

        512-267-2430
```

Source: BioCorRx